Login to Your Account



Ampyra Lower-Dose Post-Market Study Misses Endpoint

By Catherine Shaffer
Staff Writer

Monday, August 13, 2012
A post-market study by Acorda Therapeutics Inc. designed to compare a lower 5-mg dose of Ampyra (dalfampridine) to the approved 10-mg dose failed to show any benefit for the 5-mg dose and missed its primary endpoint altogether at both doses. The drug is approved for use in patients with multiple sclerosis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription